RM Silveira
YOU?
Author Swipe
View article: PRODUCTION OF “UNIVERSAL” CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS THROUGH A HIGHLY EFFICIENT CRISPR/CAS9-INDUCED KNOCKOUT OF THE ENDOGENOUS TRAC GENE
PRODUCTION OF “UNIVERSAL” CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS THROUGH A HIGHLY EFFICIENT CRISPR/CAS9-INDUCED KNOCKOUT OF THE ENDOGENOUS TRAC GENE Open
Allogeneic Chimeric Antigen Receptor (CAR) T cell therapy represents a promising approach to overcome the accessibility limitations of conventional autologous treatment. Some advantages of such allogeneic therapy include the availability o…
View article: GENETICALLY ENGINEERED T CELLS EXPRESSING HIGH AFFINITY TCR ANTI-NY-ESO-1:HLA-A*02 ARE ABLE TO CONTROL SOLID TUMOR GROWTH IN VIVO
GENETICALLY ENGINEERED T CELLS EXPRESSING HIGH AFFINITY TCR ANTI-NY-ESO-1:HLA-A*02 ARE ABLE TO CONTROL SOLID TUMOR GROWTH IN VIVO Open
Despite the remarkable success in the use of T cells expressing Chimeric Antigen Receptors (CAR) for hematologic malignances, their application to solid tumors, which represents the majority of neoplasms, remains challenging. However, T ly…
View article: T CELLS ENGINEERED TO EXPRESS A CAR ANTI-GD2 AND THE COSTIMULATORY MOLECULE GITRL ERADICATE GLIOBLASTOMA CELLS AND ARE IFNY PRODUCERS
T CELLS ENGINEERED TO EXPRESS A CAR ANTI-GD2 AND THE COSTIMULATORY MOLECULE GITRL ERADICATE GLIOBLASTOMA CELLS AND ARE IFNY PRODUCERS Open
The adoptive transfer of T lymphocytes expressing chimeric antigen receptors (CAR) has resulted in impressive complete remission rates in B-cell malignancies. However, the therapeutic efficacy of CAR-T cells is still low or non-existent ag…
View article: GENERATION OF T LYMPHOCYTES EXPRESSING ENGINEERED T CELL RECEPTOR TARGETING THE NY-ESO-1 TUMOR ANTIGEN USING A NEW GENETIC CONSTRUCT
GENERATION OF T LYMPHOCYTES EXPRESSING ENGINEERED T CELL RECEPTOR TARGETING THE NY-ESO-1 TUMOR ANTIGEN USING A NEW GENETIC CONSTRUCT Open
Immunotherapy based on the adoptive transfer of genetically modified T lymphocytes for the expression of engineered receptors has provided impressive results for hematological neoplasms. This is the case of T cells modified to express chim…
View article: OPTIMIZED PROTOCOLS OF EXPANSION OF PERIPHERAL BLOOD-DERIVED δT-CELLS FOR THE ESTABLISHMENT OF AN OFF-THE-SHELF ADVANCED CELL THERAPY AGAINST CANCER
OPTIMIZED PROTOCOLS OF EXPANSION OF PERIPHERAL BLOOD-DERIVED δT-CELLS FOR THE ESTABLISHMENT OF AN OFF-THE-SHELF ADVANCED CELL THERAPY AGAINST CANCER Open
The use of autologous T cells expressing chimeric antigen receptors (CAR) has revolutionized the treatment of hematological malignancies. However, the use of allogeneic CAR-T cells offers many advantages over autologous therapies, includin…